کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
3271344 | 1208269 | 2008 | 7 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
A Clinician's Perspective on the Use of Zoledronic Acid in the Treatment of Postmenopausal Osteoporosis
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
موضوعات مرتبط
علوم پزشکی و سلامت
پزشکی و دندانپزشکی
غدد درون ریز، دیابت و متابولیسم
پیش نمایش صفحه اول مقاله

چکیده انگلیسی
Osteoporotic fractures may lead to pain, disability, impaired quality of life, and increased risk of death, with annual health-care costs of $17 billion or more. Oral bisphosphonates, the first-line treatment for postmenopausal osteoporosis (PMO), increase bone mineral density and reduce the risk of fracture, but dosing requirements are complex and compliance and persistence are poor. The newest bisphosphonate treatment option, intravenous (IV) zoledronic acid (ZOL) every 12Â mo, has been shown to reduce the risk of vertebral, hip, and other nonvertebral fractures. Long-dosing intervals and 100% bioavailability with IV bisphosphonate therapy address some of the limitations associated with oral bisphosphonates. This is a review of the clinical trial data supporting the use of IV ZOL to reduce fracture risk, and its potential role in the management of PMO in clinical practice.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Journal of Clinical Densitometry - Volume 11, Issue 4, OctoberâDecember 2008, Pages 478-484
Journal: Journal of Clinical Densitometry - Volume 11, Issue 4, OctoberâDecember 2008, Pages 478-484
نویسندگان
E. Michael MD, FACP, FACE,